Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Cassava Sciences Inc.
Headquarters: Austin, TX, United States of America
Website: https://www.cassavasciences....
Year Founded: 1998
Status: Public
Industry Sector: HealthTechnology
CEO: Richard Jon Barry
Number Of Employees: 30
Enterprise Value: $-18,588,560
PE Ratio: -0.88
Exchange/Ticker 1: NASDAQ:SAVA
Exchange/Ticker 2: N/A
Latest Market Cap: $61,351,000
BioCentury | Jan 17, 2025
Finance
4Q24 Wrap: They all fall down
Winners, losers in biotech stock tiers in 4Q24
BioCentury | Oct 4, 2024
Finance
3Q24 Wrap: Lookin’ up at last
Winners, losers in biotech stock tiers in 3Q24
BioCentury | Sep 27, 2024
Finance
Wave financing, BioAge IPO help biotech end September strong
In BioCentury’s latest Public Equity Report, Wave raises $200M on standout DMD data and BioAge marks fourth NASDAQ IPO this month
BioCentury | Sep 10, 2024
Management Tracks
Lucas Montarce named Lilly CFO
Plus: Yong Ben hired as chief medical and development officer of TheRas, and updates from Orbital, Latigo, AAVantgarde and more
BioCentury | Jul 18, 2024
Management Tracks
Rosenberg named CFO of BeiGene
Plus: CEO Barbier, SVP Burns leave Cassava, and updates from Rezo and Haya
BioCentury | Nov 2, 2022
Management Tracks
New heads of commercial, legal at ADC
Plus Antares vet Powell lands at Lava, and updates from CymaBay, Lineage, CARsgen and more
BioCentury | Jul 28, 2022
Regulation
July 27 Quick Takes: Cidara, Melinta in deal for antifungal headed to FDA
Plus Legend gains after upsizing financing and updates from Lexicon, ObsEva, Cassava, Legend and more
BioCentury | Apr 10, 2021
Finance
1Q21 Wrap: Sliding down
Large and midcap biotechs lost value in 1Q21, but microcaps gained
BioCentury | Mar 16, 2021
Product Development
The clinical pipeline for Alzheimer’s disease: Data Byte
The early stage Alzheimer’s pipeline moves beyond amyloid
BioCentury | Feb 5, 2021
Finance
GameStop survivors target biotech shares, but ‘BioWar’ unlikely despite bolus of short-friendly stocks
Will biotech shorts ‘get burned’?
Items per page:
1 - 10 of 26